Literature DB >> 27583777

Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant.

Joseph R Francica1, Geoffrey M Lynn1, Richard Laga2, M Gordon Joyce1, Tracy J Ruckwardt1, Kaitlyn M Morabito1, Man Chen1, Rajoshi Chaudhuri3, Baoshan Zhang1, Mallika Sastry1, Aliaksandr Druz1, Kiyoon Ko1, Misook Choe1, Michal Pechar2, Ivelin S Georgiev1, Lisa A Kueltzo3, Leonard W Seymour4, John R Mascola1, Peter D Kwong1, Barney S Graham1, Robert A Seder1.   

Abstract

Structure-based vaccine design has been used to develop immunogens that display conserved neutralization sites on pathogens such as HIV-1, respiratory syncytial virus (RSV), and influenza. Improving the immunogenicity of these designed immunogens with adjuvants will require formulations that do not alter protein antigenicity. Here, we show that nanoparticle-forming thermoresponsive polymers (TRP) allow for co-delivery of RSV fusion (F) protein trimers with Toll-like receptor 7 and 8 agonists (TLR-7/8a) to enhance protective immunity. Although primary amine conjugation of TLR-7/8a to F trimers severely disrupted the recognition of critical neutralizing epitopes, F trimers site-selectively coupled to TRP nanoparticles retained appropriate antigenicity and elicited high titers of prefusion-specific, TH1 isotype anti-RSV F antibodies following vaccination. Moreover, coupling F trimers to TRP delivering TLR-7/8a resulted in ∼3-fold higher binding and neutralizing antibody titers than soluble F trimers admixed with TLR-7/8a and conferred protection from intranasal RSV challenge. Overall, these data show that TRP nanoparticles may provide a broadly applicable platform for eliciting neutralizing antibodies to structure-dependent epitopes on RSV, influenza, HIV-1, or other pathogens.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27583777     DOI: 10.1021/acs.bioconjchem.6b00370

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  16 in total

1.  A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Barney S Graham; Sang Moo Kang
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

2.  R848 or influenza virus can induce potent innate immune responses in the lungs of neonatal mice.

Authors:  Spyridon Makris; Cecilia Johansson
Journal:  Mucosal Immunol       Date:  2020-06-23       Impact factor: 7.313

Review 3.  Adjuvants: tailoring humoral immune responses.

Authors:  M Juliana McElrath
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

Review 4.  Nanoparticle vaccines against respiratory syncytial virus.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Future Virol       Date:  2020-11-30       Impact factor: 1.831

Review 5.  Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus.

Authors:  Patricia A Jorquera; Ralph A Tripp
Journal:  Vaccines (Basel)       Date:  2016-12-02

Review 6.  Nanoparticle-Based Vaccines Against Respiratory Viruses.

Authors:  Soultan Al-Halifa; Laurie Gauthier; Dominic Arpin; Steve Bourgault; Denis Archambault
Journal:  Front Immunol       Date:  2019-01-24       Impact factor: 7.561

7.  Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates.

Authors:  Joseph R Francica; Richard Laga; Geoffrey M Lynn; Gabriela Mužíková; Ladislav Androvič; Baptiste Aussedat; William E Walkowicz; Kartika Padhan; Ramiro Andrei Ramirez-Valdez; Robert Parks; Stephen D Schmidt; Barbara J Flynn; Yaroslav Tsybovsky; Guillaume B E Stewart-Jones; Kevin O Saunders; Faezzah Baharom; Constantinos Petrovas; Barton F Haynes; Robert A Seder
Journal:  PLoS Biol       Date:  2019-06-17       Impact factor: 9.593

Review 8.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14

Review 9.  Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).

Authors:  Amir Seyfoori; Mahdieh Shokrollahi Barough; Pooneh Mokarram; Mazaher Ahmadi; Parvaneh Mehrbod; Alireza Sheidary; Tayyebeh Madrakian; Mohammad Kiumarsi; Tavia Walsh; Kielan D McAlinden; Chandra C Ghosh; Pawan Sharma; Amir A Zeki; Saeid Ghavami; Mohsen Akbari
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 5.923

Review 10.  Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.

Authors:  Yinghan Chan; Sin Wi Ng; Sachin Kumar Singh; Monica Gulati; Gaurav Gupta; Sushil Kumar Chaudhary; Goh Bey Hing; Trudi Collet; Ronan MacLoughlin; Raimar Löbenberg; Brian G Oliver; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Life Sci       Date:  2021-06-24       Impact factor: 6.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.